Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Maxinovel Pharmaceuticals Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 1 distinct examiner and 1 distinct art unit. The presence of this 1 pending office action shows the current volume of activity for this entity. Practitioners should note the involvement of the 1 distinct art unit, which defines the examination environment. The coordination of the response within this technical center is a key consideration for the legal team.
SHIAO, REI TSANG is the busiest examiner for this portfolio, currently overseeing 1 pending office action. While the company workload involves 1 distinct examiner, this specific official is responsible for 1 matter. This concentration suggests that the innovations are being evaluated by a group within the Biotechnology & Pharmaceuticals field. Having 1 distinct examiner involved means that the prosecution strategy must account for the individual tendencies of this official. This examiner may bring a specific perspective to the claims, requiring a specific approach for the individual case file.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852557 | PHARMACEUTICAL COMPOSITION COMPRISING JAK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHIAO, REI TSANG | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852557 | PHARMACEUTICAL COMPOSITION COMPRISING JAK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHIAO, REI TSANG | 1691 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Maxinovel Pharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rei Tsang Shiao has the most, with 1 of Beijing Maxinovel Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
